Search results
Author(s):
Michael C Gibson
Added:
5 years ago
Dr C. Michael Gibson (Beth Israel Deaconess Medical Center, Boston, MA, US) discusses Rivaroxaban 2.5 mg BID combined with DAPT for the prevention of death/MI/stroke - a patient level data meta-analysis of the ATLAS-ACS-2 TIMI-51 and the COMMANDER HF trials
Filmed on site at CRT 2019 by Radcliffe Cardiology
Questions:
1. Why did you conduct this analysis?
2. How was data collected and…
View more
Controversy Surrounding ROCKET-AF: A Call for Transparency, But Should We Be Changing Practice?
Author(s):
Jason D Matos
,
Peter J Zimetbaum
Added:
3 years ago
Article
Author(s):
Nur A Rahmat
,
Gregory YH Lip
Added:
3 years ago
Until recently, the vitamin K antagonist (VKA, e.g. warfarin) class of drugs was the only oral anticoagulant in use. VKAs have important inter- and intra-patient variability, influenced by diet, alcohol and drugs; thus, regular anticoagulation monitoring is necessary. Indeed, VKAs offer their best efficacy and safety when the average time in therapeutic range (TTR) is >65–70 % in a particular…
View more
Author(s):
Pascal Vranckx
,
Marco Valgimigli
,
Hein Heidbuchel
Added:
3 years ago
Anticoagulation with vitamin K antagonists (VKAs) has been used for the long-term treatment and prevention of thromboembolic diseases and for stroke prevention in atrial fibrillation (AF) for the past half century. Until the last decade, VKAs were the only oral anticoagulant (OAC) agents available, and warfarin remains the most commonly prescribed OAC worldwide.1 Direct oral anticoagulants (DOACs…
View more
Author(s):
Philipp Bushoven
,
Sven Linzbach
,
Mate Vamos
,
et al
Added:
3 years ago
Atrial Fibrillation, Cardioversion and Stroke Risk
Atrial fibrillation (AF) is the most common serious chronic heart rhythm disorder with an estimated prevalence in the general population of around 1%.1 The arrhythmia affects about 2.2 million persons in the US and 4.5 million individuals in the EU. Due to the advancing age of the population, the prevalence of AF is likely to increase even…
View more
Author(s):
Yousif Ahmad
,
Gregory YH Lip
Added:
3 years ago
Atrial fibrillation (AF) leads to a prothrombotic state1 and places patients at risk of thromboembolic disease. The most common and serious complication of thromboembolism is stroke, and AF is held responsible for 25 % of all strokes.2 Strokes in the context of AF are associated with a higher mortality, longer hospital stay and lower levels of independence at discharge.3 These factors combine to…
View more
Author(s):
Jean-Yves Le Heuzey
Added:
8 years ago
Author(s):
Andreas Goette
,
Hein Heidbuchel
Added:
3 years ago
AF is the most common sustained cardiac arrhythmia and poses a significant public health challenge.1 In cases of AF, if sinus rhythm does not spontaneously return, cardioversion may be needed to alleviate symptoms and to improve cardiac performance.2 This may be performed by pharmacological methods, i.e. the administration of antiarrhythmic drugs, which is the preferred strategy in recent-onset…
View more
Author(s):
Demosthenes G Katritsis
Added:
3 years ago
Reviewing recent literature of advances in arrhythmia therapy, I have found most interesting the emergence of antidotes, both general and specific, for the non-vitamin K antagonist oral anticoagulants (NOACs). NOACs offer a relative 50 % reduction in the risk of intracranial haemorrhage and haemorrhagic stroke compared with warfarin that is also maintained in the elderly. There are no clear…
View more
Author(s):
Marco Alings
Added:
3 years ago
Atrial Fibrillation(AF) is the most common cardiac arrhythmia, with the highest prevalence in elderly patients, and is characterised by an irregular heart rhythm that may result in clots in the heart that can spread throughout the circulatory system. It is seen in approximately 2 % of the European adult population and is a significant cause of increasing healthcare costs in developed countries.1…
View more